Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Turcot syndrome × Immunotherapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 41 Melanoma 16 Neoplasm Metastasis 15 Lung Neoplasms 14 Neoplasms 11 Carcinoma, Hepatocellular 11 Esophageal Neoplasms 10 Colorectal Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Breast Neoplasms 7 Head and Neck Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Stomach Neoplasms 5 Rectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Recurrence 4 Carcinoma, Renal Cell 4 Brain Neoplasms 4 Uterine Cervical Neoplasms 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Liver Neoplasms 3 Cholangiocarcinoma 3 Sarcoma 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Neuroblastoma 2 Neoplasm, Residual 2

Interventions

pembrolizumab 10 Nivolumab 9 Ipilimumab 4 avelumab 3 Neoadjuvant Therapy 3 sintilimab 2 durvalumab 2 atezolizumab 2 Specimen Handling 2 Immune Checkpoint Inhibitors 2 toripalimab 1 tislelizumab 1 spartalizumab 1 relatlimab 1 regorafenib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 denileukin diftitox 1 danvatirsen 1 Taxes 1 Surgical Procedures, Operative 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Oxaliplatin 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07259473 2026-01-07

Pre-CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡